Generex Biotechnology provides update on Phase II trial of AE37 breast cancer ...

18-11-2013 News-Medical.netComments (0)

BiotechnologyGenerex Biotechnology

Generex Biotechnology Corporation (OTCBB: GNBT) today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel ...

Read more on News-Medical.net

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top